Tesaro, Inc. (TSRO) Appoints Grant C. Bogle As Senior Vice President And Chief Commercial Officer

WALTHAM, Mass., July 13, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Grant C. Bogle to the newly created position of Senior Vice President and Chief Commercial Officer. In this role, Mr. Bogle will report to Lonnie Moulder, CEO of TESARO, and will lead TESARO's marketing, sales, and market access teams. Mr. Bogle most recently served as Senior Vice President, Pharmaceutical and Biotech Solutions at McKesson Specialty Health, where he led the informatics, health economics and outcomes research, reimbursement access and safety services, and U.S. Oncology Clinical Research business units.

"TESARO is quickly transforming into an integrated development and commercial biopharmaceutical company," said Lonnie Moulder. "We are excited that Grant is joining the TESARO team, as his deep industry knowledge and commercial experience will be invaluable as we prepare for the potential launch of our first product, rolapitant, for the prevention of chemotherapy-induced nausea and vomiting."

Mr. Bogle has more than twenty-five years of experience in a variety of commercial roles within the biopharmaceutical industry. Previously, he served as Executive Vice President, Strategy and Emerging Businesses at US Oncology, Inc. (acquired by McKesson Corporation in 2010), and was Senior Vice President of Sales and Marketing for Millennium Pharmaceuticals, where he was responsible for the oncology product, VELCADE. Prior to joining Millennium, Mr. Bogle held senior sales and marketing roles with Roche Pharmaceuticals, Knoll Pharmaceuticals, DuPont, and American Critical Care (a division of American Hospital Supply Corp). He holds an MBA from Columbia University and an undergraduate degree in economics from Dartmouth College.


TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing, and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include statements regarding the potential launch of rolapitant and its potential indication. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties surrounding ongoing discussions with and actions by the U.S. FDA with respect to the rolapitant New Drug Application, and other matters that could affect the rolapitant approval, uncertainties regarding certain expenditures, and other matters that could affect the availability or commercial potential of our drug candidates . TESARO undertakes no obligation to update or revise any forward-looking statements. For further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2014.

CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or [email protected]